FDA Approves Asciminib, Drug With Novel Action in CML
This first-in-class STAMP inhibitor is approved for use in patients with chronic myeloid leukemia who have developed resistance to tyrosine kinase inhibitors.
Source: medscape.com
Specifically Targeting News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Specifically Targeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Specifically Targeting Today - Breaking & Trending Today